Article

Greenphire Expands Agreement With Merck

Greenphire has announced an expansion of its agreement with Merck, known as MSD outside the US and Canada. This expanded agreement now includes the use of Greenphire's ClinCard with rideshare integration for participants across Merck's clinical development network.

Greenphire's ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on participants. ClinCard does not impose costs on sites and helps ensure patients are reimbursed in a timely manner so research sites can focus on conducting clinical trials.

Reference

Greenphire Expands Agreement with Merck to Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide. (2023, March 13). Cision PR Newswire.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
© Dr_Microbe - © Dr_Microbe - stock.adobe.com
August 2nd 2025

Monthly Ivermectin Cuts Malaria Infection by 26% in Kenyan Phase III BOHEMIA Trial

Andy Studna, Senior Editor
In the BOHEMIA study, once-monthly ivermectin over 3 months significantly reduced malaria incidence versus albendazole in children aged 5 to 15 years, supporting its role as a novel vector-control tool amid rising insecticide resistance.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 2nd 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
Image Credit: Adobe Stock Images/MUdaylah
August 2nd 2025

Obicetrapib Shows Alzheimer’s Biomarker Reduction in Phase III BROADWAY Trial

Andy Studna, Senior Editor
In a pre-specified sub-study of the BROADWAY trial, obicetrapib 10 mg significantly reduced plasma p-tau217 levels in patients with ASCVD, including ApoE4 carriers, suggesting dual potential to lower LDL-C and impact Alzheimer’s disease progression.
Unifying Industry to Better Understand GCP Guidance
August 2nd 2025

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Kisunla Slows Cognitive and Functional Decline Over Three Years in Phase III Alzheimer Long-Term Extension Trial
August 2nd 2025

Kisunla Slows Cognitive and Functional Decline Over Three Years in Phase III Alzheimer Long-Term Extension Trial

Don Tracy, Associate Editor
Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with early Kisunla treatment, including reduced risk of disease progression and high rates of amyloid clearance in early Alzheimer disease.
© Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com
August 2nd 2025

Cardiff Reports 49% Response Rate With Onvansertib in RAS-Mutated Colorectal Cancer

Andy Studna, Senior Editor
In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in first-line RAS-mutated metastatic colorectal cancer, with a favorable safety profile and dose-dependent efficacy across endpoints.
© 2025 MJH Life Sciences

All rights reserved.